Latest Manufacturing Capacity News

IperionX’s Definitive Feasibility Study for its Titan Project in Tennessee reveals a robust 14-year mine plan producing critical heavy rare earths, titanium minerals, and zircon with strong financial returns and US government backing.

Independent U.S. Army and WMTR testing confirms IperionX's Ti-6Al-4V fasteners outperform high-strength Grade 8 steel in torque-to-yield and tensile strength, underpinning a secure domestic titanium supply chain.

Tetratherix Limited secures $15 million via institutional placement plus a capped $2 million share purchase plan at a 14% discount, aiming to fast-track manufacturing expansion and commercial partnerships.

IperionX has commissioned a cutting-edge six-axis SACMI powder metallurgy press in Virginia, tripling its titanium manufacturing capacity and enabling production of complex components for defense and aerospace markets.

Li-S Energy has secured vital approvals to airfreight lithium-sulfur prototype cells to the United States, paving the way for direct engagement with US defence and drone sectors.

Anteris Technologies reported a $22.9 million net loss in Q1 2026 but bolstered its cash position to $283 million following a $320 million capital raise. The company is scaling manufacturing and clinical activities for its DurAVR transcatheter heart valve, with US patient enrolment now underway in the pivotal PARADIGM Trial.

Zimi Limited secures A$1.4 million via a discounted share placement, including director participation, to fund manufacturing and sales expansion.

Merino & Co. reported Q3 FY26 revenue of A$441,558 with new domestic and China purchase orders supporting its growth strategy, while cash reserves fell to A$654,282 due to investments in production and marketing.

Clarity Pharmaceuticals’ Phase II Co-PSMA trial confirms its Cu-SAR-bisPSMA PET imaging detects more than twice the prostate cancer lesions versus standard care, driving patient management changes. Phase III AMPLIFY recruitment closes, manufacturing deals inked, and cash sits near $198 million.

Little Green Pharma (ASX:LGP) posted record quarterly and annual revenues driven by a surge in European sales, improved cashflow, and reduced debt. The company is on track to complete its merger with Cannatrek by June 1, 2026, while benefiting from the US rescheduling of medicinal cannabis to Schedule III.

AML3D has maintained a steady $2.2 million quarterly revenue run rate and secured $12.5 million in new orders during 3Q26, pushing its total orders for FY2026 to $29 million. The company is aggressively expanding its US manufacturing footprint and making initial inroads into UK and European defence markets.

IperionX has transitioned its Virginia titanium operations to continuous 24/7 production, ramping proprietary HAMR™ titanium powder output to 4.2 metric tons in March and targeting 200 tons per annum by the end of 2026. Alongside manufacturing capacity expansions and strong U.S. Department of War backing, the company advances its critical minerals project in Tennessee.